Skip to main content
TipRanks
Go Ultimate75% OFF

InDex Pharmaceuticals Holding AB (FLERIE) Stock Price & Analysis

2 Followers

FLERIE Stock Chart & Stats

kr 13.00kr 0.00(0.00%)
At close: 5:30 PM GMT+1
kr 12.5kr 15kr 17.5kr 20Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
SEK 12.45 - SEK 13.10
52-Week Range
SEK 12.30 - SEK 34.21
Previous Close
SEK 13.00
Volume
N/A
Average Volume (3M)
79.20K
Market Cap
SEK 1.18B
Enterprise Value
SEK 1.15B
Total Cash (Recent Filing)
SEK 265.10M
Total Debt (Recent Filing)
SEK 1.60M
Price to Earnings (P/E)
―
Beta
0.04
Next Earnings
Jan 20, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Exceptionally Low Leverage

Minimal debt materially reduces interest and refinancing pressure, giving InDex greater financial flexibility than a highly leveraged biotech. This balance-sheet strength can help preserve strategic options and support continued clinical or partnering activity despite current losses.

Substantial Asset And Equity Base

The company retains a substantial reported asset and equity base relative to its very low debt burden. Although those resources are not currently producing positive returns, they provide a stronger financial foundation for executing development plans and negotiating future strategic transactions.

Focused Immunology Pipeline And Partnering Model

A focused therapeutic strategy around immunology and a lead ulcerative-colitis candidate gives the company a clear development and partnering proposition. Upfront, milestone, research funding, or royalty opportunities could provide scalable monetization if clinical and regulatory progress is achieved.

Bears Say

Persistent Cash Burn

Ongoing negative operating and free cash flow means the business is consuming cash rather than funding itself. If this pattern continues, InDex will need successful partnering, additional financing, or other capital sources to sustain clinical development and operations.

Severe And Volatile Profitability

Extremely large losses and unstable revenue demonstrate that InDex has not yet established a dependable earnings engine. This weak operating profile limits internal reinvestment capacity and makes future financial performance highly dependent on development and commercialization outcomes.

Dependence On Clinical And Partnering Success

The company’s revenue model relies on securing suitable partners and reaching clinical, regulatory, and commercialization milestones before recurring product economics can emerge. Delays or unsuccessful development outcomes could therefore postpone or reduce upfront, milestone, and royalty income.

FLERIE FAQ

What was InDex Pharmaceuticals Holding AB’s price range in the past 12 months?
InDex Pharmaceuticals Holding AB lowest stock price was kr 12.30 and its highest was kr 34.21 in the past 12 months.
What is InDex Pharmaceuticals Holding AB’s market cap?
InDex Pharmaceuticals Holding AB’s market cap is kr 1.18B.
When is InDex Pharmaceuticals Holding AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were InDex Pharmaceuticals Holding AB’s earnings last quarter?
InDex Pharmaceuticals Holding AB released its earnings results on Oct 15, 2026. The company reported -kr 3.236 earnings per share for the quarter.
Is InDex Pharmaceuticals Holding AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does InDex Pharmaceuticals Holding AB pay dividends?
InDex Pharmaceuticals Holding AB does not currently pay dividends.
What is InDex Pharmaceuticals Holding AB’s EPS estimate?
InDex Pharmaceuticals Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InDex Pharmaceuticals Holding AB have?
InDex Pharmaceuticals Holding AB has 86,697,700 shares outstanding.
What happened to InDex Pharmaceuticals Holding AB’s price movement after its last earnings report?
InDex Pharmaceuticals Holding AB reported an EPS of -kr 3.236 in its last earnings report. Following the earnings report the stock price went down -0.635%.
Which hedge fund is a major shareholder of InDex Pharmaceuticals Holding AB?
Currently, no hedge funds are holding shares in SE:FLERIE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology